Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting. Fekadu G, Wang Y, You JHS. Int J Tuberc Lung Dis 2024;28:12-17.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fekadu G, Wang Y, You JHS. Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting. Int J Tuberc Lung Dis 2024;28:12-17.
PMID: 38303041